U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07218666) titled 'Zanzalintinib in Men With Aggressive Variant Prostate Cancer' on Oct. 16.
Brief Summary: This is a multi-center single arm phase II study to evaluate the antitumor activity of zanzalintinib 60mg orally (PO) once daily in subjects with AVPC. Zanzalintinib may continue until radiographic progression (or beyond), intolerable adverse events, or withdrawal of consent. As long as the subject is clinically stable, subjects may receive study treatment even after radiographic progression, until they are no longer clinically benefiting from the study treatment in the opinion of the treating Investigator, or they need subsequent systemic antic...